Aprotinin and the protease-activated receptor 1 thrombin receptor: Antithrombosis, inflammation, and stroke reduction

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 10, Issue 2, 2006, Pages 132-142

  Day, J R S ^a   Landis, R C ^b   Taylor, K M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Antithrombosis; Cardiopulmonary bypass; Inflammation; PAR1; Stroke; Thrombin

Indexed keywords

APROTININ; CD11B ANTIGEN; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 1; FIBRINOGEN; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN IB; HEPARIN COFACTOR II; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR; PROTEINASE ACTIVATED RECEPTOR 1; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; THROMBOMODULIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; HEMOSTASIS; HUMAN; NEUROPROTECTION; NONHUMAN; PERIOPERATIVE PERIOD; RECEPTOR DOWN REGULATION; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION;

ANIMALS; APROTININ; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; ENDOTHELIAL CELLS; HUMANS; RECEPTOR, PAR-1; SERINE PROTEINASE INHIBITORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBIN; THROMBOSIS;

EID: 33747511469     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253206288997     Document Type: Conference Paper

References (76)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30: 10363-10370.
2. Berndt MC, Phillips DR. Interaction of thrombin with platelets: purification of the thrombin substrate. Ann N Y Acad Sci. 1981; 370:87-95.
3. Bar-Shavit R, Benezra M, Eldor A, et al. Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul. 1990;1:453-463.
4. O'Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells: contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem. 2000;275:13502-13509.
5. Bar-Shavit R, Kahn A, Fenton JW, Wilner GD. Chemotactic response of monocytes to thrombin. J Cell Biol. 1983;96:282-285.
6. Zimmerman GA, McIntyre TM, Prescott SM. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest. 1985;76:2235-2246.
7. Gurwitz D, Cunningham DD. Thrombin modulates and reverses neuroblastoma neurite outgrowth. Proc Natl Acad Sci USA. 1988;85:3440-3444.
8. Gustafson GT, Lerner U. Thrombin, a stimulator of bone resorption. Biosci Rep. 1983;3:255-261.
9. Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Thromb Haemost. 1997;78:501-511.
10. Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor: issues and opportunities. J Clin Invest. 1992;89:351-355.
11. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
12. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature. 1991;353: 674-677.
13. Scarborough RM, Naughton MA, Teng W, et al. Tethered ligand agonist peptides: structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem. 1992;267:13146-13149.
14. Brass LF, Pizarro S, Ahuja M, et al. Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling. J Biol Chem. 1994; 269:2943-2952.
15. Bouton MC, Jandrot-Perrus M, Moog S, Cazenave JP, Guillin MC, Lanza F. Thrombin interaction with a recombinant N-terminal extracellular domain of the thrombin receptor in an acellular system. Biochem J. 1995;305(Pt 2):635-641.
16. Seiler SM, Peluso M, Michel IM, et al. Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist. Biochem Pharmacol. 1995;49:519-528.
17. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998; 394:690-694.
18. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA. 1998;95:6642-6646.
19. O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene. 2001; 20:1570-1581.
20. Striggow F, Riek-Burchardt M, Kiesel A, et al. Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur J Neurosci. 2001;14:595-608.
21. Turgeon VL, Milligan CE, Houenou LJ. Activation of the protease-activated thrombin receptor (PAR)-1 induces motoneuron degeneration in the developing avian embryo. J Neuropathol Exp Neurol. 1999;58:499-504.
22. Turgeon VL, Lloyd ED, Wang S, Festoff BW, Houenou LJ. Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. J Neurosci. 1998;18:6882-6891.
23. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry. 1999;38:4572-4585.
24. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wildtype and tPA-deficient mice. Nat Med. 1998;4:228-231.
25. Gingrich MB, Traynelis SF. Serine proteases and brain damage: is there a link? Trends Neurosci. 2000;23:399-407.
26. Junge CE, Sugawara T, Mannaioni G, et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci USA. 2003;100:13019-13024.
27. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
28. Taylor KM. SIRS: the systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 1996;61:1607-1608.
29. Day JRS, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg. 2005;3:129-140.
30. Society of Critical Care Medicine Consensus Conference. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
31. Reiter R, Derhaschnig U, Spiel A, et al. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost. 2003;90:898-903.
32. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg. 1998;66:2145-2152.
33. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg. 1998; 65:352-358.
34. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33:479-494.
35. Castiglioni GC, Lojacono L, Tamborini G. [Effects of trypsin and kallikrein inhibition in acute pancreatitis]. Arch Ital Chir. 1965;91:365-376.
36. Tice DA, Worth MH Jr. Recognition and treatment of postoperative bleeding associated with open-heart surgery. Ann N Y Acad Sci. 1968;146:745-753.
37. Royston D, Bidstrup BD, Taylor KM, Sapsford RN. Aprotinin decreases the need for post-operative blood transfusions in patients having open heart surgery. Bibl Cardiol. 1988;43:73-82.
38. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 1987;44:640-645.
39. Bidstrup BP, Royston D, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery. Lancet. 1988;1:366-367.
40. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-428.
41. von Berghoff A, Glatzel U. Inhibition of the fibrinolytic potential by Trasylol. Med Klin. 1963;12:476.
42. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2000; 69:1192-1197.
43. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658-1662.
44. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000;120:361-369.
45. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-9.
46. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83:696-700.
47. Garcia-Szabo RR, Malik AB. Pancreatitis-induced increase in lung vascular permeability: protective effect of Trasylol. Am Rev Respir Dis. 1984;129:580-583.
48. Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg. 2001;122:123-128.
49. Day JR, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2006;131;21-27.
50. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1993;106:1008-1016.
51. Voisine P, Ruel M, Khan TA, et al. Differences in gene expression profiles of diabetic and nondiabetic patients undergoing cardiopulmonary bypass and cardioplegic arrest. Circulation. 2004;110(suppl 1):II280-II286.
52. Pola R, Flex A, Gaetani E, Flore R, Serricchio M, Pola P. Synergistic effect of -174 G/C polymorphism of the interleukin-6 gene promoter and 469 E/K polymorphism of the intercellular adhesion molecule-1 gene in Italian patients with history of ischemic stroke. Stroke. 2003;34: 881-885.
53. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671-675.
54. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg. 1998;66:747-753.
55. Mohr R, Martinowitz U, Golan M, Ayala L, Goor DA, Ramot B. Platelet size and mass as an indicator for platelet transfusion after cardiopulmonary bypass. Circulation. 1986;74(5 Pt 2): III153-III158.
56. Kondo C, Tanaka K, Takagi K, et al. Platelet dysfunction during cardiopulmonary bypass surgery. With special reference to platelet membrane glycoproteins. ASAIO J. 1993;39: M550-M553.
57. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction: a scanning electron microscope study. Circulation. 1992; 86(suppl): II405-II409.
58. Lavee J, Savion N, Smolinsky A, Goor DA, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg. 1992;53:477-481.
59. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:788-796.
60. Wildevuur CR, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg. 1989; 3:533-537.
61. Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 1997;96:569-574.
62. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg. 2000;120:370-378.
63. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation. 2004;110:2597-2600.
64. Andrade-Gordon P, Derian CK, Maryanoff BE, et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther. 2001;298:34-42.
65. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8:1161-1165.
66. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304:855-861.
67. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995;92:2236-2244.
68. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg. 1996;62:1575-1577.
69. Murkin JM. Attenuation of neurologic injury during cardiac surgery. Ann Thorac Surg. 2001;72:S1838-S1844.
70. Frumento RJ, O'Malley CM, Bennett-Guerrero E. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg. 2003;75:479-483.
71. Smith PK, Datta SK, Muhlbaier LH, Samsa G, Nadel A, Lipscomb J. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. Ann Thorac Surg. 2004;77:635-642.
72. Harmon DC, Ghori KG, Eustace NP, O'Callaghan SJ, O'Donnell AP, Shorten GD. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth. 2004;51:1002-1009.
73. Jurk K, Jahn UR, Van Aken H, et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost. 2004;91: 334-344.
74. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb Haemost. 1993;70:253-258.
75. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost. 1993;70:259-262.
76. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;44:1143-1148.